Androgen hormone inhibits expression of iNOS and COX-2 protein in rat vascular smooth muscle cell

Korean Journal of Physiology and Pharmacology

Volumn 9, Issue 4, 2005, Pages 215-221

  Bae, Hwa Young ^a   Park, Ji Eun ^b   Jeon, Eun Mi ^b   Kang, Young Jin ^b   Lee, Kwang Youn ^b   Choi, Hyoung Chul ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

COX 2; Dihydrotestosterone; iNOS; Testosterone; VSMC

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; PROTEIN TYROSINE KINASE; SEX HORMONE; SYNAPTOTAGMIN; TESTOSTERONE;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; INCUBATION TIME; INFLAMMATION; INHIBITION KINETICS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 24644482617     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci 76: 2315-2328, 2005
2. Barzilay J, Freedland E. Inflammation and its association with glucose disorders and cardiovascular disease. Treat Endocrinol 2: 85-94, 2003
3. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002
4. Choi HC, Lee KY. CD14 glycoprotein expressed in vascular smooth muscle cells. J Pharmacol Sci 95: 65-70, 2004
5. Choi HC, Lee SG, Kim JH, Kim JY, Sohn LTD, Ha JH, Lee KY, Kim WJ. Lipopolysaccharide inhibits proliferation of the cultured vascular smooth muscle cells by stimulating inducible nitric oxide synthase and subsequent activation of guanylate cyclase. Korean J Physiol Pharmacol 5: 343-351, 2001
6. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66: 462-471, 2005
7. Ding AQ, Stallone JN. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 91: 2742-2750, 2001
8. Di Rosa M, Radomski M, Carnuccio, R, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun 172: 1246-1252, 1990
9. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957, 2004
10. Festa A, Haffner SM. Inflammation and cardiovascular disease in patients with diabetes: lessons from the Diabetes Control and Complications Trial. Circulation 111: 2414-2415, 2005
11. Greenberg SS, Jie O, Zhao X, Wang JF, Giles TD. The potential mechanism of induction of inducible nitric oxide synthase mRNA in alveolar macrophages by lipopolysaccharide and its suppression by ethanol, in vivo. Alcohol Clin Exp Res 22(5 Suppl): 260S-265S, 1998.
12. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87: 3632-3639, 2002
13. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103: 1382-1385, 2001
14. Hasegawa K, Ohashi Y, Ishikawa K, Yasue A, Kato R, Achiwa Y, Nishio, E, Udagawa Y. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. Int J Oncol 26: 1419-1428, 2005
15. Hashimura K, Sudhir K, Nigro J, Ling S, Williams MR, Komesaroff PA, Little PJ. Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. Endocrinology 146: 2085-2090, 2005
16. Hutchison SJ, Sudhir K, Chou TM, Sievers RE, Zhu BQ, Sun YP, Deedwania PC, Glantz SA, Parmley WW, Chatterjee K. Testosterone worsens endothelial dysfunction associated with hyper-cholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. J Am Coll Cardiol 29: 800-807, 1997
17. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613, 1998
18. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol 290: 69-73, 1995
19. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Long-term effects of finasteride on prostate tissue composition. Urology 53: 574-580, 1999
20. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GE, Schmidt J, Taylor AM, Lee M, Waldstreicher J. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 167: 2105-2108, 2002
21. Miki S, Takeyama N, Tanaka T, Nakatani T. Immune dysfunction in endotoxicosis: role of nitric oxide produced by inducible nitric oxide synthase. Crit Care Med 33: 716-720, 2005
22. Nachtigal P, Kopecky M, Solichova. D, Zdansky P, Semecky V. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol 57: 197-203, 2005
23. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68: 341-350, 2004
24. Oka M, Maeda S, Koga N, Kato K, Saito T. A modified colorimetric MTT assay adapted for primary cultured hepatocytes: application to proliferation and cytotoxicity assays. Biosci Biotechnol Biochem 56: 1472-1473, 1992
25. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 90: 2708-2711, 2005
26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-833, 2002
27. Sainz J, Osuna A, Wangensteen R, de Dios Luna J, Rodriguez-Gomez I, Duarte J, Moreno JM, Vargas F. Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension. Exp Physiol 89: 155-162, 2004
28. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999
29. Shimomura-Shimizu M, Sugiyama KI, Muroi M, Tanamoto KI. Alachlor and carbaryl suppress lipopolysaccharide-induced iNOS expression by differentially inhibiting NF-kappaB activation. Biochem Biophys Res Commun 332: 793-799, 2005
30. Stemme V, Swedenborg J, Claesson H, Hansson GK. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20: 146-152, 2000
31. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl 22: 300-306, 1999
32. Teoh H, Quan A, Man RY. Acute impairment of relaxation by low levels of testosterone in porcine coronary arteries. Cardiovasc Res 45: 1010-1018, 2000
33. Valenti S, Fazzuoli L, Giusti M. Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. J Endocrinol Invest 26: 522-526, 2003
34. Vane JR. COX-2 inhibitors: background knowledge for clinical use. Introduction. Inflamm Res 47: S77, 1998
35. Vo PA, Lad B, Tomlinson JA, Francis S, Ahluwalia A. Autoregulatory role of endotheliumderived nitric oxide (NO) on Lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem 280: 7236-7243, 2005
36. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 329: 247-256, 1993
37. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 87: 176-181, 2002
38. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91: 1154-1160, 1995